Clearside Biomedical Inc


Prices are adjusted according to historical splits.

Clearside Biomedical Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$58.56 million
Book Value:
Revenue TTM:
$1.33 million
Operating Margin TTM:
Gross Profit TTM:
$1.12 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Clearside Biomedical Inc had its IPO on 2016-06-02 under the ticker symbol CLSD.

The company operates in the Healthcare sector and Biotechnology industry. Clearside Biomedical Inc has a staff strength of 36 employees.

Stock update

Shares of Clearside Biomedical Inc opened at $0.96 at the start of the last trading session i.e. 2023-03-30.

The stocks traded within a range of $0.95 - $0.98, and closed at $0.96.

This is a -0.31% slip from the previous day's closing price.

A total volume of 87,259 shares were traded at the close of the day’s session.

In the last one week, shares of Clearside Biomedical Inc have slipped by -5.25%.

Clearside Biomedical Inc's Key Ratios

Clearside Biomedical Inc has a market cap of $58.56 million, indicating a price to book ratio of 3.927 and a price to sales ratio of 2.6392.

In the last 12-months Clearside Biomedical Inc’s revenue was $1.33 million with a gross profit of $1.12 million and an EBITDA of $-30132000. The EBITDA ratio measures Clearside Biomedical Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Clearside Biomedical Inc’s operating margin was -2281.61% while its return on assets stood at -40.17% with a return of equity of -135.64%.

In Q4, Clearside Biomedical Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 98.7%.

Clearside Biomedical Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-0.5 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Clearside Biomedical Inc’s profitability.

Clearside Biomedical Inc stock is trading at a EV to sales ratio of 0.7441 and a EV to EBITDA ratio of -4.8278. Its price to sales ratio in the trailing 12-months stood at 2.6392.

Clearside Biomedical Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$51.30 million
Total Liabilities
$5.78 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Clearside Biomedical Inc ended 2023 with $51.30 million in total assets and $0 in total liabilities. Its intangible assets were valued at $51.30 million while shareholder equity stood at $10.61 million.

Clearside Biomedical Inc ended 2023 with $0 in deferred long-term liabilities, $5.78 million in other current liabilities, 61000.00 in common stock, $-288438000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $48.26 million and cash and short-term investments were $48.26 million. The company’s total short-term debt was $349,000 while long-term debt stood at $0.

Clearside Biomedical Inc’s total current assets stands at $49.40 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.05 million and inventory worth $0.

In 2023, Clearside Biomedical Inc's operating cash flow was $-91000.00 while its capital expenditure stood at $154754.

Comparatively, Clearside Biomedical Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Clearside Biomedical Inc stock is currently trading at $0.96 per share. It touched a 52-week high of $2.54 and a 52-week low of $2.54. Analysts tracking the stock have a 12-month average target price of $5.8.

Its 50-day moving average was $1.24 and 200-day moving average was $1.33 The short ratio stood at 2.17 indicating a short percent outstanding of 0%.

Around 745.2% of the company’s stock are held by insiders while 2815.8% are held by institutions.

Frequently Asked Questions About Clearside Biomedical Inc

The stock symbol (also called stock or share ticker) of Clearside Biomedical Inc is CLSD

The IPO of Clearside Biomedical Inc took place on 2016-06-02

Similar Industry Stocks (Biotechnology)

Last Price
Taoping Inc (TAOP)
Haleon plc (HLNCF)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price


Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.


900 North Point Parkway, Alpharetta, GA, United States, 30005